The insufficient results of immunotherapy in effectively treating these myeloid malignancies to date highlight the urgent need to address the gap of knowledge regarding the nuanced interactions between CD8+ T cells and neoplastic cells, and how they influence treatment outcomes. This evidence concerns the gene CD8A and myeloid neoplasm.